GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483700
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
- Conditions
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT04454437
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese PLA General Hospital, Beijing, China
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 59
- Registration Number
- NCT04431453
- Locations
- 🇺🇸
Johns Hopkins Children's Center, Baltimore, Maryland, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
- Conditions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04323761
- Locations
- 🇺🇸
Charlton Memorial Hospital, Fall River, Massachusetts, United States
🇺🇸Lawrence General Hospital, Lawrence, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Expanded Access for IMMU-132
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04320693
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT04319198
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 539
- Registration Number
- NCT04313881
- Locations
- 🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center; Clinical Research Organization, Philadelphia, Pennsylvania, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4891
- Registration Number
- NCT04292899
- Locations
- 🇺🇸
UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States
🇺🇸Prisma Health Richland Hospital, Columbia, South Carolina, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1113
- Registration Number
- NCT04292730
- Locations
- 🇺🇸
Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States
🇺🇸Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT04211909
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷The Catholic University of Korea, Seoul Saint Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-D, Korea, Republic of